Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

NCT07294950 on ClinicalTrials.gov · last registry update 2026-02-11

A small phase 3 — 98 participants, against a typical 424. Due to report September 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Differences in changes in body weight between each study group. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Mount Sinai Hospital, Canada
Sponsor type: Other
Enrollment: 98
Started: 2026-02-01
Primary completion: 2028-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Differences in changes in body weight between each study group

Conditions studied

Obesity (Disorder) · Weight Change · Blood Pressure Monitoring · Appetite Regulation

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.